openPR Logo
Press release

Tabex, the quit smoking supplement mentioned as weight loss solution

03-16-2021 02:25 PM CET | Health & Medicine

Press release from: Sopharma

The plant-based supplement Tabex, used to quit smoking could be repurposed.

The plant-based supplement Tabex, used to quit smoking could be repurposed.

The fact that smokers tend to be less overweight than non-smokers prompted a new study. The findings from this study can be harnessed and used as a weight loss treatment, researchers say.

They discovered a specific receptor in the brain to which nicotine binds and which is also responsible for suppressing appetite. In the study, researchers manipulated these receptors in the brains of mice, causing them to eat noticeably less.

Elissa J. Chesler, Ph.D., works to relate precisely measured and characterized mouse behaviors with specific aspects of human disorders, agreed that these results are likely to apply to humans as well, because the processes in our cells are very similar to those in mice.

"We've been able to find out exactly where appetite suppression occurs in the brain and which receptors are responsible for it," said Marina Rachel Picciotto, Ph.D., a neuroscientist known for her work on the role of nicotine in addiction, memory, and reward behaviors.

"There are already possible treatments available," said Dr. Picciotto and referred to Tabex, a plant-based supplement used in Eastern Europe to quit smoking. "It may be that treatments that are already being used to quit smoking could be repurposed," she said.

Based on these findings, treatment with cytisine, the main ingredient in Tabex, would reduce the risk of weight gain in smokers who want to quit smoking, as well as increase the chances to lose weight in non-smokers.

About Tabex:

Tabex from the Bulgarian pharmaceutical company Sopharma is a product for smoking cessation. Taking Tabex leads to a gradual cessation of nicotine addiction, respectively smoking cessation within 25 days.

The active ingredient of Tabex – cytisine is an alkaloid isolated from the plant Cytisus Laburnum (acacia "golden rain"). Its chemical structure is similar to nicotine and competes for the same receptors in the brain – the so-called nicotinic acetylcholine receptors.

However, cytisine has a stronger ability to bind to these receptors and thus "protects" them from nicotine by preventing it from binding to them. As a result, the symptoms of nicotine addiction gradually decrease and disappear.

For more information visit: https://tabexoriginal.com

Sopharma
16 Iliensko Shosse
1220 Sofia
Bulgaria

Contact: Ivan Ivanov

Sopharma produces high-quality and reliable medicines, such as Tabex, for the effective treatment of a wide range of diseases. Therefore, the company's efforts are focused on analyzing and forecasting the changing demands of the market and providing the necessary products.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tabex, the quit smoking supplement mentioned as weight loss solution here

News-ID: 2256921 • Views: 1907

More Releases for Tabex

Smoking Cessation Nicotine De Addiction Products Market Analysis By 2025 | Top K …
The global smoking cessation and nicotine de-addiction products market is projected to register a staggering expansion at 12.3% CAGR during the forecast period 2017 to 2025, according to a report by Persistence Market Research (PMR). The report estimates the market to reach revenues worth US$ 9036.2 Mn in 2017; by 2025 this number is further expected to surpass US$ 20,000 Mn. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/4226 Hospital Pharmacies
Smoking Cessation Nicotine De Addiction Products Market is projected to register …
The global smoking cessation and nicotine de-addiction products market is projected to register a staggering expansion at 12.3% CAGR during the forecast period 2017 to 2025, according to a report by Persistence Market Research (PMR). The report estimates the market to reach revenues worth US$ 9036.2 Mn in 2017; by 2025 this number is further expected to surpass US$ 20,000 Mn. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/4226 Hospital Pharmacies
Smoking Cessation and Nicotine De-addiction Products Market is expected to surpa …
The global smoking cessation and nicotine de-addiction products market is projected to register a staggering expansion at 12.3% CAGR during the forecast period 2017 to 2025, according to a report by Persistence Market Research (PMR). The report estimates the market to reach revenues worth US$ 9036.2 Mn in 2017; by 2025 this number is further expected to surpass US$ 20,000 Mn. Hospital Pharmacies to Remain the Largest Distribution Channel in the
ecom presents new industrial tablet TabEx 02-The Machine Maker
The Pepperl+Fuchs brand ecom will be presenting the next generation of its groundbreaking tablet series for hazardous areas Tab-Ex at the HANNOVER MESSE 2018 (from April 23 to 27) in Hall 9, stand D76. The industrial tablet Tab-Ex 02 combines top performance with innovative applications such as augmented reality. It is ideally suited for IoT-capable applications and simplifies data exchange with SCADA / DCS systems, enterprise resource planning systems (SAP, IBM
Global Smoking Cessation and Nicotine De-addiction Products Market : North Ameri …
North America is expected to remain the most lucrative market for smoking cessation and nicotine de-addiction products, with sales estimated to reach revenues worth US$ 10,259.5 Mn by 2025-end. In North America, innovative players in nicotine replacement therapy (NRT) are focusing on introduction of novel treatment alternatives including selective partial agonists of nicotine receptors (varenicline), and Tabex (cytosine plant-based alkaloid). In addition, MPOWER initiative taken by the WHO has successfully
Sales Revenue of Smoking Cessation Products Market to Rise at 12.3% CAGR by 2025
Asia Pacific (APAC) is projected to register the highest CAGR in the global smoking cessation and nicotine de-addiction products market through 2025. Strict laws and rules issued against smoking in APAC countries, such as China, are expected to drive demand for smoking cessation and de-addiction products in this region. According to a draft bill, smoking will be prohibited in public places such as public transport and workplaces in China. China